Earnings Conference Call Overview: Forian Inc. held its Q2 2025 earnings conference call on August 13, 2025, featuring CEO Max Wygod and CFO Michael Vesey discussing the company's financial results and future outlook.
Forward-Looking Statements Warning: The management emphasized that their remarks may include forward-looking statements, which are subject to risks and uncertainties that could cause actual results to differ from projections made during the call.
FORA
$2.13+Infinity%1D
Analyst Views on FORA
Wall Street analysts forecast FORA stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for FORA is 2.10 USD with a low forecast of 2.10 USD and a high forecast of 2.10 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
Wall Street analysts forecast FORA stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for FORA is 2.10 USD with a low forecast of 2.10 USD and a high forecast of 2.10 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
0 Buy
1 Hold
0 Sell
Hold
Current: 2.130
Low
2.10
Averages
2.10
High
2.10
Current: 2.130
Low
2.10
Averages
2.10
High
2.10
Roth Capital
Buy -> Neutral
downgrade
$5
2025-11-17
Reason
Roth Capital
Price Target
$5
2025-11-17
downgrade
Buy -> Neutral
Reason
Roth Capital downgraded Forian to Neutral from Buy with a price target of $2.10, down from $5.
Roth Capital
Richard Baldry
Buy -> Neutral
downgrade
$5
2025-11-17
Reason
Roth Capital
Richard Baldry
Price Target
$5
2025-11-17
downgrade
Buy -> Neutral
Reason
Roth Capital analyst Richard Baldry downgraded Forian to Neutral from Buy with a price target of $2.10, down from $5. The company reported good Q3 results but the shares offer little upside given the majority of shareholders have chosen to take Forian private at $2.10 per share, the analyst tells investors in a research note.
About FORA
Forian Inc. is a healthtech company. The Company is a provider of data science-driven information and analytics solutions to the life science, healthcare and financial services industries. The Company provides a suite of data management capabilities and proprietary information and analytics solutions to optimize and measure the operational, clinical and financial performance of customers. It has expertise in acquiring, integrating, normalizing and commercializing large-scale healthcare data assets. Its data ingestion, transformation, delivery services and business intelligence platforms are managed entirely via cloud-based data centers located in the United States. The Company’s offerings include commercial, Real World Evidence (RWE) and market access solutions and proprietary data-driven insights to optimize the operational, clinical and financial performance of its customers. The Company’s solutions include CHRONOS, Chartis, RWE and Kyber Data Science.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
